Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Pfizer’s mixed Q3; delayed US approval for Janssen/Legend’s CAR-T; promising new data in RSV; Dr Reddy’s lays out more COVID product plans; and experts dissect decentralized trials.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 29 October 2021, including: Pfizer Inc.’s mixed Q3; delayed US approval for Janssen Pharmaceutical Cos./Legend Biotech Corp.’s CAR-T; promising new data in RSV; Dr. Reddy's Laboratories Ltd.’s lays out more COVID-19 product plans; and experts dissect decentralized trials.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Comirnaty Gives Booster Shot To Pfizer Q3 Sales" - Scrip, 2 Nov, 2021.)
(Also see "Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use" - Scrip, 1 Nov, 2021.)
(Also see "Dr Reddy’s Gears For Sputnik Pediatric Shot, Molnupiravir Upside" - Scrip, 1 Nov, 2021.)
(Also see "Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?" - Scrip, 3 Nov, 2021.)